SavedAdd your journal

Journals / Uludağ Üniversitesi Tıp Fakültesi Dergisi / 2026 / Cilt: 52

Investigation of Hepatitis E Virus Seroprevalence at Bursa Uludağ University Faculty of Medicine Hospital

Bursa Uludağ Üniversitesi Tıp Fakültesi Hastanesi’nde Hepatit E Virüsü Seroprevalansının Araştırılması

Ayşe Melda Payaslıoğlu(Bursa Uludağ University, Faculty of Medicine, Department of Medical Microbiology, Bursa, Türkiye.)0009-0004-1725-0644
İmran Sağlık(Bursa Uludağ University, Faculty of Medicine, Department of Medical Microbiology, Bursa, Türkiye.)0000-0003-0864-4989
Pages
—
Publication Date
2026-03-26
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Broader epidemiological studies incorporating molecular confirmation methods are recommended for a more definitive understanding of HEV status.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study aimed to determine Hepatitis E Virus (HEV) seroprevalence in patients at a tertiary center in Southern Marmara, Türkiye, and evaluate regional epidemiology.
📊
Key Findings & Data:A retrospective analysis of 288 serum samples (May 2023–June 2025) was performed.
💡
Conclusion & Impact:Broader epidemiological studies incorporating molecular confirmation methods are recommended for a more definitive understanding of HEV status.
🔬Design:Araştırma Makalesi
📍Scope:2023 Verileri
⚙️Variables:Hepatit E Virüsü · HEV Seroprevalansı · Serolojik Testler

Abstract

This study aimed to determine Hepatitis E Virus (HEV) seroprevalence in patients at a tertiary center in Southern Marmara, Türkiye, and evaluate regional epidemiology. A retrospective analysis of 288 serum samples (May 2023–June 2025) was performed. Anti-HEV IgM and IgG were measured by ELISA, and data were statistically analyzed. Anti-HEV IgG positivity was 1.7%, anti-HEV IgM positivity was 2.1%, and 96.2% of the samples were negative for both markers. No acute HEV infection was confirmed in IgM-positive patients. Children with IgM positivity often had hematological diseases and Epstein-Barr or parvovirus co-infections, suggesting possible cross-reactivity. HEV prevalence is low in Southern Marmara. Due to serological test limitations and false positives, molecular methods like HEV RNA testing are needed for accurate acute infection diagnosis. Broader epidemiological studies incorporating molecular confirmation methods are recommended for a more definitive understanding of HEV status.

Özet

Bu çalışma, Türkiye’nin Güney Marmara Bölgesi’nde yer alan üçüncü basamak bir sağlık kuruluşuna başvuran hastalarda Hepatit E Virüsü (HEV) seroprevalansını belirlemeyi ve bölgenin epidemiyolojik durumunu değerlendirmeyi amaçlamıştır. Mayıs 2023–Haziran 2025 tarihleri arasında 288 serum örneği retrospektif olarak analiz edilmiştir. Anti-HEV IgM ve IgG antikorları ELISA yöntemiyle ölçülmüş ve veriler istatistiksel olarak değerlendirilmiştir. Anti-HEV IgG pozitifliği %1,7, anti-HEV IgM pozitifliği %2,1 olarak saptanmış; örneklerin %96,2’sinde her iki belirteç de negatif bulunmuştur. IgM pozitif hastalarda akut HEV enfeksiyonu doğrulanmamıştır. IgM pozitifliği saptanan çocuk hastaların çoğunda hematolojik hastalıklar ile Epstein-Barr virüsü veya parvovirüs ko-enfeksiyonları bulunması, olası çapraz reaktiviteyi düşündürmüştür. Güney Marmara Bölgesi’nde HEV prevalansının düşük olduğu görülmüştür. Serolojik testlerin sınırlılıkları ve yalancı pozitiflikler nedeniyle, akut enfeksiyonun doğru tanısı için HEV RNA gibi moleküler yöntemlerin kullanılması gerekmektedir. HEV epidemiyolojisinin daha net ortaya konabilmesi için moleküler doğrulama yöntemlerini içeren daha geniş kapsamlı epidemiyolojik çalışmalara ihtiyaç vardır.

🔖

Cite This Article

Payaslıoğlu, A. M., Sağlık, İ., *, A. M. P. (2026). Investigation of Hepatitis E Virus Seroprevalence at Bursa Uludağ University Faculty of Medicine Hospital. Uludağ Üniversitesi Tıp Fakültesi Dergisi, Cilt: 52. https://doi.org/10.32708/uutfd.1778142

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (33)

  1. Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, et al. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. Liver Int. 2020;40(7):1516–1528. doi:10.1111/liv.14468
  2. Aggarwal R, Naik S. Epidemiology of hepatitis E: Current status. J Gastroenterol Hepatol. 2009;24(9):1484–1493. doi:10.1111/j.1440-1746.2009.05933.x
  3. Echevarría JM. Light and darkness: Prevalence of hepatitis E virus infection among the general population. Scientifica (Cairo). 2014;2014:481016. doi:10.1155/2014/481016
  4. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):116–138. doi:10.1128/CMR.00057-13
  5. Wang B, Meng XJ. Hepatitis E virus: Host tropism and zoonotic infection. Curr Opin Microbiol. 2020;59:8–15. doi:10.1016/j.mib.2020.07.004
  6. World Health Organization. Hepatitis E. Published April 10, 2025. [Accessed June 23, 2025]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-e
  7. Kamar N, Dalton HR. Transmission and epidemiology of hepatitis E virus genotype 3 and 4 infections. J Clin Virol. 2014;59(3):185–189. doi:10.1016/j.jcv.2014.04.001
  8. Alkan S, Gürsul NC, Önder T. Türkiye kaynaklı hepatit E virüs seroprevalans çalışmalarının gözden geçirilmesi. Dent Med J Rev. 2022;4(1):59–71.
  9. Mızrakçı S. Türkiye’deki hemodiyaliz hastalarında hepatit E seroprevalans oranlarının havuz analizi yöntemi ile araştırılması. J Contemp Med. 2022;33(1):500–503.
  10. Kaleli İ, Şengül M, Özen N, Akşit F. Honaz kırsalında hepatit E virüs seropozitifliği. Pamukkale Univ GCRIS Database. 2017.
  11. Leblebicioğlu H, Özaras R. Hepatitis E virus infection in Türkiye: A systematic review. Ann Clin Microbiol Antimicrob. 2018;17(1):17. doi:10.1186/s13642-018-0134-7
  12. Özcan N, Kaydaş S, Kazar A, Temiz H. Unveiling the hepatitis E seroprevalence: Insights from Dicle University Hospital in Southeastern Türkiye. Dicle Med J. 2024;51(1):64–71. doi:10.5798/dicletip.1451584
  13. Lemon SM, Walker CM. Hepatitis A virus and hepatitis E virus: Emerging and re-emerging enterically transmitted hepatitis viruses. Cold Spring Harb Perspect Med. 2019;9(10):a031823. doi:10.1101/cshperspect.a031823
  14. Velavan TP, Pallerla SR, Johne R, Todt D, Walther T, Wedemeyer H. Hepatitis E: An update on One Health and clinical medicine. Liver Int. 2021;41(7):1462–1473. doi:10.1111/liv.14846
  15. Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20(1):23–31. doi:10.1159/000149370
  16. Cao K, Wu X, Yang M, Chen C, Zhang X, Jiang D, et al. Prevalence of hepatitis E virus in China from 1997 to 2022: A systematic review and meta-analysis. Front Public Health. 2023;11:1243408. doi:10.3389/fpubh.2023.1243408
  17. Lemos MPD, Junaid S, de Almeida LP, Albuquerque MPB, Dos Santos AAC, Souza AI. Seroprevalence of hepatitis E virus infection in the Americas: Estimates from a systematic review and meta-analysis. One Health. 2022;14:100383. doi:10.1016/j.onehlt.2022.100383
  18. Abravanel F, Lhomme S, El Costa H, Schvartz B, Peron JM, Kamar N, et al. Rabbit hepatitis E virus infections in humans, France. Emerg Infect Dis. 2017;23(7):1191–1193. doi:10.3201/eid2307.170318
  19. Aspinall EJ, Couturier E, Faber M, Said B, Ijaz S, Tavoschi L, et al. Hepatitis E virus infection in Europe: Surveillance and descriptive epidemiology of confirmed cases, 2005–2015. Euro Surveill. 2017;22(26):30561. doi:10.2807/1560-7917.ES.2017.22.26.30561
  20. Yaşar O, Karataylı E, Cengiz G. HEV seroprevalence in blood donors in Türkiye by two commercial total anti-HEV Ab ELISA kits. J Med Virol. 2019;91(12):2174–2181. doi:10.1002/jmv.25567
  21. Sezgin O, Yaraş S, Tezcan Ülger S, Aslan G, Tiftik EN. The prevalence of hepatitis E virus infection in the adult Turkish population: A systematic review and meta-analysis. Turk J Gastroenterol. 2021;32(9):782–789. doi:10.5152/tjg.2021.20870
  22. Bayhan Gİ, Demirören K, Güdücüoğlu H. Hepatit E virüsüne karşı antikorların Doğu Türkiye’deki çocuklarda prevalansı. Turk Arch Pediatr. 2016;51(3):148–151. doi:10.5152/TurkPediatriArs.2016.3483
  23. European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256–1271. doi:10.1016/j.jhep.2018.03.005
  24. Abravanel F, Lhomme S, Sandres-Sauné K, Dubois M, Izopet J, Kamar N. High prevalence of hepatitis E virus antibodies in Corsica (France) in blood donors. J Clin Virol. 2019;116:23–27. doi:10.1016/j.jcv.2019.04.007
  25. Colson P, Kaba M, Moreau J, Brouqui P. Hepatitis E virus in southwestern France: An epidemiological study of seroprevalence in blood donors and wild boar. Euro Surveill. 2020;25(5):1900103. doi:10.2807/1560-7917.ES.2020.25.5.1900103
  26. Öztürk H, Özsoy M, Tuna A, Varlıbaş A, Cesur S, Aksoy A, et al. Investigation of hepatitis E virus seroprevalence and risk factors in hemodialysis patients. Front Public Health. 2025;13:1574361. doi:10.3389/fpubh.2025.1574361
  27. Balaban HY, Aslan AT, Akdoğan-Kittana FN, Alp A, Dağ O, Ayar ŞN, et al. Hepatitis E virus prevalence and associated risk factors in high-risk groups: a cross-sectional study. Turk J Gastroenterol. 2022;33(7):615-624. doi:10.5152/tjg.2022.21493
  28. Jiménez de Oya N, Galindo I, Gironés O, Duizer E, Escribano JM, Saiz JC. Serological immunoassay for detection of hepatitis E virus on the basis of genotype 3 open reading frame 2 recombinant proteins produced in Trichoplusia ni larvae. J Clin Microbiol. 2009;47(10):3276–3282. doi:10.1128/JCM.01024-09
  29. Bendall R, Ellis V, Ijaz S, Ali R, Dalton HR. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82(5):799–805. doi:10.1002/jmv.21656
  30. Trémeaux P, Lhomme S, Chapuy-Regaud S, Peron JM, Alric L, Kamar N, et al. Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. J Clin Virol. 2016;82:1–5. doi:10.1016/j.jcv.2016.06.010
  31. Hyams C, Mabayoje DA, Copping R. Serological cross-reactivity to CMV and EBV causes problems in the diagnosis of acute hepatitis E virus infection. J Med Virol. 2014;86(3):478–483. doi:10.1002/jmv.23827
  32. Fogeda M, De Ory F, Avellón A, Echevarría J. Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E. J Clin Virol. 2009;45(3):259–261. doi:10.1016/j.jcv.2009.07.004
  33. Gray J, Caldwell J, Sillis M. The rapid serological diagnosis of infectious mononucleosis. J Infect. 1992;25(1):39–46. doi:10.1016/0163-4453(92)90051-8